Patents Assigned to Sankyo Company Limited
  • Intermediate for production of nucleoside analog and method for producing the same
    Patent number: 9738681
    Abstract: A compound represented by the general formula (III) which serves as an intermediate of an oligonucleotide analog having stable and excellent antisense or antigene activity or having excellent activity as a detection reagent (probe) for a specific gene or as a primer for the initiation of amplification of a specific gene can be produced at high yields regardless of the type of nucleobase by a method comprising reacting a compound represented by the general formula (II) or a salt thereof with a trimethylsilylated compound obtained from a compound represented by the general formula (IVb), wherein X, Y, Z, A, R, and B are as defined in claim 1.
    Type: Grant
    Filed: June 17, 2013
    Date of Patent: August 22, 2017
    Assignee: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Makoto Koizumi, Koji Morita, Miho Sato
  • CRYSTAL OF PYRROLE DERIVATIVE AND METHOD FOR PRODUCING THE SAME
    Publication number: 20170233341
    Abstract: The present invention provides a production intermediate of an atropisomer of a pyrrole derivative having excellent mineralocorticoid receptor antagonistic activity, a method for producing the same, and a crystal thereof. A method for producing an atropisomer of a pyrrole derivative including a step of resolving a compound represented by the following general formula (I) [wherein R1 represents a methyl group or a trifluoromethyl group, R2 represents a hydrogen atom or a C1-C3 alkoxy group, and n represents an integer selected from 1 to 3] into its atropisomers, characterized by using an optically active amine having a cinchonine skeletal formula, and a crystal of (S)-1-(2-hydroxyethyl)-4-methyl-N-[4-(methylsulfonyl)phenyl]-5-[2-(trifluoromethyl)phenyl]-1H-pyrrole-3-carboxamide.
    Type: Application
    Filed: April 28, 2017
    Publication date: August 17, 2017
    Applicant: Daiichi Sankyo Company, Limited
    Inventors: Masashi Watanabe, Takahiro Okachi, Michiaki Kawahara, Hiroshi Nagasawa, Noritada Sato, Takashi Takita, Gen Hasegawa
  • Anti-Orai1 Antibody
    Publication number: 20170226203
    Abstract: It is intended to provide a therapeutic and/or prophylactic agent for transplant rejections, immunological diseases, allergic diseases, inflammatory diseases, thrombosis, cancers, etc., targeting human Orai1. The present invention provides, for example, a pharmaceutical composition comprising an antibody that specifically recognizes human Orai1 and has the activity of inhibiting human T cell activation.
    Type: Application
    Filed: August 6, 2015
    Publication date: August 10, 2017
    Applicant: Daiichi Sankyo Company, Limited
    Inventors: Tomoaki Komai, Takako Kimura, Daichi Baba, Yoshikuni Onodera, Kento Tanaka, Takashi Kagari, Anri Aki, Nobumi Nagaoka
  • Substituted phenylazole derivative
    Patent number: 9725438
    Abstract: Compounds are provided having an excellent hypoglycemic effect and ? cell- or pancreas-protecting effects, or pharmaceutically acceptable salts thereof, and a pharmaceutical composition having an excellent therapeutic effect and/or prophylactic effect on type 1 diabetes, type 2 diabetes, and the like, which cause hyperglycemia due to abnormal glucose metabolism. A compound represented by general formula (I), or a pharmaceutically acceptable salt thereof, is disclosed.
    Type: Grant
    Filed: December 1, 2015
    Date of Patent: August 8, 2017
    Assignee: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Shigeo Yamanoi, Hidenori Namiki, Yuichi Ochiai, Madoka Hoshino, Koji Matsumoto
  • Crystals of dispiropyrrolidine derivatives
    Patent number: 9718830
    Abstract: Crystals of a dispiropyrrolidine compound or a salt thereof which inhibits the action of Mdm2 are provided. The present invention provides crystals of (3?R,4?S,5?R)-N-[(3R,6S)-6-carbamoyltetrahydro-2H-pyran-3-yl]-6?-chloro-4?-(2-chloro-3-fluoropyridin-4-yl)-4,4-dimethyl-2?-oxo-1?,2?-dihydrodispiro[cyclohexane-1,2?-pyrrolidine-3?,3?-indole]-5?-carboxamide or a salt thereof which inhibits Mdm2 and has anti-tumor activity. The present invention also provides a medicament comprising the same.
    Type: Grant
    Filed: December 6, 2016
    Date of Patent: August 1, 2017
    Assignee: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Shoko Yoshida, Yuuichi Sugimoto
  • Crystals of dispiropyrrolidine derivatives
    Patent number: 9718831
    Abstract: Crystals of a dispiropyrrolidine compound or a salt thereof which inhibits the action of Mdm2 are provided. The present invention provides crystals of (3?R,4?S,5?R)—N-[(3R,6S)-6-carbamoyltetrahydro-2H-pyran-3-yl]-6?-chloro-4?-(2-chloro-3-fluoropyridin-4-yl)-4,4-dimethyl-2?-oxo-1?,2?-dihydrodispiro[cyclohexane-1,2?-pyrrolidine-3?,3?-indole]-5?-carboxamide or a salt thereof which inhibits Mdm2 and has anti-tumor activity. The present invention also provides a medicament comprising the same.
    Type: Grant
    Filed: December 6, 2016
    Date of Patent: August 1, 2017
    Assignee: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Shoko Yoshida, Yuuichi Sugimoto
  • METHOD FOR IMPROVED HIGH-LEVEL SECRETORY PRODUCTION OF PROTEIN
    Publication number: 20170211063
    Abstract: The object of the present invention is to provide a production system that is capable of high-level secretory production of a protein (and in particular, a protein with a complicated structure such as a structure with S—S bonds) in a host cell such as yeast and is suitable for industrial production with high safety that does not require explosion-proof facilities. The present invention provides a transformed yeast into which a chaperone gene has been introduced and in which the aox1 gene and/or the protease gene have been disrupted and a method for producing a protein involving the use of such transformed yeast.
    Type: Application
    Filed: July 29, 2015
    Publication date: July 27, 2017
    Applicant: Daiichi Sankyo Company, Limited
    Inventors: Koichi NONAKA, Takeshi SUZUKI, Masashi TSUDA, Satoshi BABA, Kimihisa ICHIKAWA, Yasunori CHIBA, Takehiko YOKO-O, Rie ITO
  • PYRIDINE COMPOUNDS
    Publication number: 20170210755
    Abstract: The present invention relates to a compound or a pharmacologically acceptable salt thereof having excellent tissue non-specific alkaline phosphatase inhibitory activity. The present invention provides a compound represented by the formula (I): wherein R1 represents a hydrogen atom, an optionally substituted C1-6 alkyl group, or the like, R2 and R3 are the same or different and each represent a hydrogen atom, an optionally substituted C1-6 alkyl group, or the like, R4 and R5 are the same or different and each represent a hydrogen atom, an optionally substituted C1-6 alkyl group, or the like, R6 represents a hydrogen atom or the like, each R7 may be the same or different and may each represent an optionally substituted C1-6 alkoxy group or the like, X represents —CH?, —C(—R7)?, or —N?, and m represents 1 to 4, or a pharmacologically acceptable salt thereof.
    Type: Application
    Filed: April 6, 2017
    Publication date: July 27, 2017
    Applicants: Daiichi Sankyo Company, Limited, Sanford Burnham Prebys Medical Discovery Institute
    Inventors: Shojiro Miyazaki, Yuko Yamamoto, Keisuki Suzuki, Masaharu Inui, Masanori Izumi, Kaori Soma, Anthony Pinkerton, Taeko Shinozaki
  • Anti-FGFR2 antibodies and methods of use thereof for treating cancer
    Patent number: 9714298
    Abstract: The present invention provides an antibody which binds to a fibroblast growth factor receptor.
    Type: Grant
    Filed: April 9, 2013
    Date of Patent: July 25, 2017
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Toshiaki Ohtsuka, Chigusa Yoshimura, Toshinori Agatsuma, Atsushi Urano, Takako Kimura, Yumi Matsui, Tatsuji Matsuoka, Jun Hasegawa, Yasuki Kamai, Reimi Kawaida
  • Pharmaceutical composition
    Patent number: 9707296
    Abstract: To provide pharmaceutical preparation exhibiting satisfactory dissolution property in a wide pH range. The pharmaceutical composition is characterized by containing (A) N1-(5-chloropyridin-2-yl)-N2-((1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-{[(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)carbonyl]amino}cyclohexyl)ethanediamide, represented by the following formula (1), a pharmacologically acceptable salt thereof, or a hydrate of any of these, and (B) one or more species selected from the group consisting of a sugar alcohol and a water-swelling additive.
    Type: Grant
    Filed: August 12, 2015
    Date of Patent: July 18, 2017
    Assignee: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Masazumi Kojima, Yoshio Kuno, Hiroaki Nakagami, Shinji Sagasaki, Koichi Ishidoh, Gaku Sekiguchi
  • Peptide library
    Patent number: 9708382
    Abstract: The present invention provides a peptide library comprising a plurality of mutant peptides based on the extracellular binding domain of the TACI protein. The mutant peptides of the library have the capacity to bind to target molecules other than the endogenous TACI ligands. The present invention further provides a peptide library comprising a plurality of mutant peptides each comprising an amino acid sequence of SEQ ID NO: 1 in the Sequence Listing.
    Type: Grant
    Filed: August 1, 2013
    Date of Patent: July 18, 2017
    Assignee: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Tohru Takahashi, Naoya Shinozaki, Takeshi Takizawa, Takako Kimura
  • Polynucleotides and polypeptide sequences involved in the process of bone remodeling
    Patent number: 9695419
    Abstract: This invention relates, in part, to unique and newly identified genetic polynucleotides involved in the process of bone remodeling, variants and derivatives of the polynucleotides and corresponding polypeptides, uses of the polynucleotides, polypeptides, variants and derivatives, and methods and compositions for the amelioration of symptoms caused by bone remodeling disorders. Disclosed in particular are the isolation and identification of polynucleotides polypeptides variants and derivatives involved in osteoclast activity, validation of the identified polynucleotides for their potential as therapeutic targets and use of the polynucleotides, polypeptides, variants and derivatives for the amelioration of disease states and research purposes.
    Type: Grant
    Filed: April 20, 2015
    Date of Patent: July 4, 2017
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Roy Rabindranauth Sooknanan, Gilles Bernard Tremblay, Mario Filion
  • TRICYCLIC BENZOXABOROLES AS ANTIBACTERIAL AGENTS
    Publication number: 20170174709
    Abstract: The present invention provides a tricyclic compound represented by general formula (I), a pharmaceutical salt thereof, or a stereoisomer thereof exhibits excellent antibacterial activity against Gram-negative bacteria resistant bacteria thereof, and also being excellent in terms of safety. Furthermore, the present invention provides production processes, pharmaceutical compositions comprising a tricyclic compound, a pharmaceutically acceptable salt thereof, or a stereoisomer thereof as an active ingredient and use thereof as a pharmaceutical agent. The compounds of the present invention are useful for the treatment and/or prevention of disease such as complicated urinary tract infections (cUTIs), nosocomial pneumonia, intra-abdominal infections (IAIs) or bacteremia.
    Type: Application
    Filed: December 29, 2016
    Publication date: June 22, 2017
    Applicant: Daiichi Sankyo Company, Limited
    Inventors: Ajay Soni, Aditi Agarwal, Sangram Shesharao Deshmukh, Kedar Padmakar Purnapatre, Shinji Marumoto
  • Anti-ROBO4 antibody
    Patent number: 9683040
    Abstract: The present invention relates to an antibody having an anti-angiogenesis activity. More specifically, the present invention relates to an antibody against ROBO4 and a pharmaceutical composition containing the antibody. An object of the present invention is to provide an anti-ROBO4 antibody having an anti-angiogenesis effect, a pharmaceutical composition or the like comprising the antibody, a method for suppressing angiogenesis using the antibody, etc. Another object of the present invention is to provide a method for producing the antibody. The antibody of the present invention activates the downstream signal of ROBO4 and has a suppressive activity against cell migration induced by VEGF or bFGF. The antibody of the present invention also exhibits an anti-angiogenesis effect in in-vivo models.
    Type: Grant
    Filed: April 26, 2013
    Date of Patent: June 20, 2017
    Assignee: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Yoshitaka Isumi, Toshiyuki Sato, Jun Hasegawa, Tatsuya Inoue
  • Crystal of pyrrole derivative and method for producing the same
    Patent number: 9676713
    Abstract: The present invention provides a production intermediate of an atropisomer of a pyrrole derivative having excellent mineralocorticoid receptor antagonistic activity, a method for producing the same, and a crystal thereof. A method for producing an atropisomer of a pyrrole derivative including a step of resolving a compound represented by the following general formula (I) [wherein R1 represents a methyl group or a trifluoromethyl group, R2 represents a hydrogen atom or a C1-C3 alkoxy group, and n represents an integer selected from 1 to 3] into its atropisomers, characterized by using an optically active amine having a cinchonine skeletal formula, and a crystal of (S)-1-(2-hydroxyethyl)-4-methyl-N-[4-(methylsulfonyl)phenyl]-5-[2-(trifluoromethyl)phenyl]-1H-pyrrole-3-carboxamide.
    Type: Grant
    Filed: November 15, 2016
    Date of Patent: June 13, 2017
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Masashi Watanabe, Takahiro Okachi, Michiaki Kawahara, Hiroshi Nagasawa, Noritada Sato, Takashi Takita, Gen Hasegawa
  • Dicarboxylic acid compound
    Patent number: 9670173
    Abstract: It is an object of the present invention to provide a medicament for preventing or treating hyperphosphatemia. Solution: A compound represented by a general formula (I) or a pharmacologically acceptable salt thereof. (In the formula, R1: a methyl group or the like, R2: a hydrogen atom or the like, R3: a hydrogen atom or the like, A: a cyclohexyl ring or the like, X: CH or the like, Y: CH or the like, Z: CH or the like, and n: 2 or the like).
    Type: Grant
    Filed: September 30, 2016
    Date of Patent: June 6, 2017
    Assignee: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Yoshikazu Uto, Mikio Kato, Hidenori Takahashi, Yasuyuki Ogawa, Osamu Iwamoto, Hiroko Kono, Kazumasa Aoki
  • Cyclopropanecarboxylic acid derivative
    Patent number: 9662310
    Abstract: A compound represented by the following general formula (I) or a pharmacologically acceptable salt thereof, wherein R1 represents a C1 to C6 alkyl group which may be substituted by one to three groups selected from substituent group A, or the like (substituent group A: a hydroxy group, a halogeno group, a cyano group, a nitro group, an amino group, a carboxy group, a C1 to C3 alkyl group, etc.); R2, R3, and R8 each independently represent a hydrogen atom or a C1 to C3 alkyl group; R4, R5, R6, R7, R9, and R10 each independently represent a hydrogen atom or the like; and R11 represents a hydrogen atom or the like, has TAFIa enzyme inhibitory activity and is useful as a therapeutic drug for myocardial infarction, angina pectoris, acute coronary syndrome, cerebral infarction, deep vein thrombosis, pulmonary embolism, or the like.
    Type: Grant
    Filed: February 3, 2015
    Date of Patent: May 30, 2017
    Assignee: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Tsutomu Nagata, Jun Kobayashi, Yoshiyuki Onishi, Masamichi Kishida, Kengo Noguchi
  • ENA nucleic acid pharmaceuticals capable of modifying splicing of mRNA precursors
    Patent number: 9657050
    Abstract: Oligonucleotides having a nucleotide sequence complementary to nucleotide numbers such as 2571-2607, 2578-2592, 2571-2592, 2573-2592, 2578-2596, 2578-2601 or 2575-2592 of the dystrophin cDNA (Gene Bank accession No. NM_004006.1) and therapeutic agents for muscular dystrophy comprising such oligonucleotides.
    Type: Grant
    Filed: September 18, 2015
    Date of Patent: May 23, 2017
    Assignees: Daiichi Sankyo Company, Limited, Orphan Disease Treatment Institute Co., Ltd.
    Inventors: Masafumi Matsuo, Yasuhiro Takeshima, Makoto Koizumi
  • ENA nucleic acid pharmaceuticals capable of modifying splicing of mRNA precursors
    Patent number: 9657049
    Abstract: Oligonucleotides having a nucleotide sequence complementary to nucleotide numbers such as 2571-2607, 2578-2592, 2571-2592, 2573-2592, 2578-2596, 2578-2601 or 2575-2592 of the dystrophin cDNA (Gene Bank accession No. NM_004006.1) and therapeutic agents for muscular dystrophy comprising such oligonucleotides.
    Type: Grant
    Filed: November 9, 2012
    Date of Patent: May 23, 2017
    Assignees: Orphan Disease Treatment Institute Co., Ltd., Daiichi Sankyo Company, Limited
    Inventors: Masafumi Matsuo, Yasuhiro Takeshima, Makoto Koizumi
  • Polypeptide cleavage method using OmpT protease variant
    Patent number: 9657323
    Abstract: A polypeptide cleavage method characterized in that arginine or lysine is at the P1 position of a desired cleavage site in a polypeptide, an amino acid other than aspartic acid, glutamic acid or proline is at the P1? position, a single basic amino acid or two or three consecutive basic amino acids are situated at any site in the amino acid sequence from the P10 position to the P3 position or from the P3? position to the P5? position (with the proviso that a single basic amino acid is not situated at the P6 or P4 position), and OmpT protease or its variant enzyme having a substitution at the 97th amino acid from the N-terminus is used to cleave the desired cleavage site in the polypeptide.
    Type: Grant
    Filed: September 29, 2004
    Date of Patent: May 23, 2017
    Assignee: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Kazuaki Okuno, Masayuki Yabuta